

NCRI CLL Trials

Andy Pettitt

**On behalf of the CLL sub-group of
the NCRI**

2nd March 2011

Acknowledgements

NCRI CLL Trials Sub-group



Peter Hillmen (Chair)
Samir Agrawal
Adrian Bloor
Daniel Catovsky
Dena Cohen
Claire Dearden
Steve Devereux
Andrew Duncombe
Monica Else
Chris Fegan
Nicola Fenwick
George Follows
John Gribben

Terry Hamblin
Ben Kennedy
Mike Leach
Scott Marshall
Estella Matutes
Don Milligan
Amit Nathwani
David Oscier
Chris Pepper
Andy Pettitt
Chris Pocock
Sue Richards
Anna Schuh



Alex Smith
Anna Chalmers
Gill Eddison
Walter Gregory

Dena Cohen
David Philips
Emma Lindop
Julia Brown

Roche, GSK, Genzyme, Celgene, Napp for supporting studies

NCRI CLL Trials

- 1. Trials for patients without co-morbidity (“considered fit for FCR”)**
- 2. Trials for patients with co-morbidity (“not considered fit for FCR”)**
- 3. Consolidation/maintenance trials**
- 4. Trials for patients with p53 deletion or dysfunction**
- 5. Other trials**

Trials in previously untreated CLL

	Previous/Closed Trials	Currently Open Trials	Future Trials
Patients considered fit for FCR	<p>LRF CLL4 – in follow-up</p>	<p>ADMIRE – FCR vs FCM-R (n=102/218 patients)</p> <p>ARCTIC - FCR vs FCM-miniR (n=68/206)</p>	<p>?FCR vs FCM-R</p>
Patients considered unfit for FCR	<p>CLL208 (Chlorambucil + rituximab) – recruitment closed Oct '09</p>	<p>CLL7 (Complement -1) Chl +/- ofatumumab - 403/444 patients recruited</p>	<p>RiAltO (Chl-Of vs Benda-Of)</p>

Trials in CLL not requiring therapy by current criteria

	Previous/Closed Trials	Currently Open Trials	Future Trials
Consolidation	CLL207 (alemtuzumab)	-	CLL8 - CLARET (alemtuzumab vs observation) – CTAAC Application for funding
Poor risk Stage A CLL	-	RESPECT (lenalidomide)	-
Good risk Stage A CLL	-		CLEAR (antibiotic therapy)

Trials in CLL – targeted therapy

	Previous/Closed Trials	Currently Open Trials	Future Trials
Richter's Transformation	-	CHOP-Of	-
Relapsed CLL	CLL201 (FCM vs FCM-R)	Complement-2 (FC vs FC-ofatumumab)	CLL212 (FC-megaOf)
Refractory CLL	CLL202 (CamFlud)	-	CLL210 (CamDex Rev)
17p deleted CLL	CLL206 (CamPred)	-	CLL210 (CamDex Rev)
11q del CLL (T-PLL)		PiCLLe (PARP inhibitor)	